Diversified Trust Co Sells 2,273 Shares of West Pharmaceutical Services, Inc. $WST

Diversified Trust Co cut its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 47.8% in the 1st quarter, Holdings Channel reports. The firm owned 2,478 shares of the medical instruments supplier’s stock after selling 2,273 shares during the period. Diversified Trust Co’s holdings in West Pharmaceutical Services were worth $621,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Holocene Advisors LP purchased a new position in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $49,085,000. Nordea Investment Management AB lifted its stake in shares of West Pharmaceutical Services by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier’s stock valued at $4,122,000 after purchasing an additional 4,477 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of West Pharmaceutical Services by 7.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 236,963 shares of the medical instruments supplier’s stock valued at $62,163,000 after purchasing an additional 16,919 shares during the period. Birch Hill Investment Advisors LLC boosted its position in shares of West Pharmaceutical Services by 11.5% during the fourth quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock valued at $41,862,000 after purchasing an additional 15,678 shares in the last quarter. Finally, Brendel Financial Advisors LLC bought a new stake in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $3,742,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at West Pharmaceutical Services

In other news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Chad Winters sold 896 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares in the company, valued at approximately $457,920.41. The trade was a 37.04% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is owned by company insiders.

West Pharmaceutical Services Stock Up 2.0%

WST stock opened at $347.34 on Friday. West Pharmaceutical Services, Inc. has a twelve month low of $206.80 and a twelve month high of $352.31. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. The firm has a market cap of $24.54 billion, a PE ratio of 46.44, a price-to-earnings-growth ratio of 2.85 and a beta of 1.18. The business has a 50 day moving average of $312.15 and a 200 day moving average of $275.06.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The business had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. During the same quarter in the previous year, the business earned $1.45 earnings per share. The firm’s quarterly revenue was up 21.0% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, research analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on WST. Zacks Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Evercore restated an “outperform” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, April 27th. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Finally, Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $310.00 to $400.00 in a research report on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $340.09.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.